2026 John H. Griffin: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	112	904	802	566	492	627	43876
Medicine	113	4980	4674	2703	2506	633	44338

Overview

John H. Griffin is affiliated with the Scripps Research Institute in the United States. Their research primarily spans the field of Medicine, with a focus on Hematology, Molecular Biology, Cardiology and Cardiovascular Medicine, Genetics, and Neurology.

The main research topics covered in their work include:

Blood Coagulation and Thrombosis Mechanisms
Venous Thromboembolism Diagnosis and Management
Acute Ischemic Stroke Management
Atrial Fibrillation Management and Outcomes
Coagulation, Bradykinin, Polyphosphates, and Angioedema
COVID-19 Clinical Research Studies
Extracellular vesicles in disease

John H. Griffin has contributed to several recent publications, including:

"Understanding COVID-19-associated coagulopathy" (2022), published in Nature Reviews. Immunology
"Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression" (2022), published in Nature Communications
"Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently" (2020), published in Circulation Research
"Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect" (2021), published in Blood
"COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation" (2020), published in Research and Practice in Thrombosis and Haemostasis

Frequent co-authors collaborating with John H. Griffin include:

José A. Fernández
Laurent O. Mosnier
Hiroshi Deguchi
Berislav V. Zloković
Gaku Kimura

They have published extensively in several scientific venues. The publication venues with the highest number of their contributions are:

Blood
Journal of Thrombosis and Haemostasis
Zenodo (CERN European Organization for Nuclear Research)
OPAL (Open@LaTrobe) (La Trobe University)
Research and Practice in Thrombosis and Haemostasis

Best Publications

Deficiency of protein C in congenital thrombotic disease.

John H. Griffin;Bruce Evatt;Theodore S. Zimmerman;Alice J. Kleiss

1849
Citations
The cytoprotective protein C pathway.

Laurent O. Mosnier;Berislav V. Zlokovic;John H. Griffin

960
Citations
Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology

Tilman M. Hackeng;John H. Griffin;Philip E. Dawson

828
Citations
Endothelial and Antithrombotic Actions of HDL

Chieko Mineo;Hiroshi Deguchi;John H. Griffin;Philip W. Shaul

799
Citations
Plasma protein S deficiency in familial thrombotic disease.

Hans Peter Schwarz;Hans Peter Schwarz;Michael Fischer;Michael Fischer;Pierre Hopmeier;Pierre Hopmeier;Mary Ann Batard;Mary Ann Batard

739
Citations
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.

Tong Cheng;Dong Liu;John H. Griffin;José A. Fernández

723
Citations
Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]

JH Griffin;B Evatt;C Wideman;JA Fernandez

694
Citations
Anticoagulant protein C pathway defective in majority of thrombophilic patients.

John H. Griffin;Bruce Evatt;Bruce Evatt;Carol Wideman;Carol Wideman;Jose A. Fernandez;Jose A. Fernandez

690
Citations
Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction Analysis From the Primary Angioplasty in Myocardial Infarction Trials

Gregg W. Stone;David Cox;Eulogio Garcia;Bruce R. Brodie

683
Citations
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme

Richard A. Marlar;Alice J. Kleiss;John H. Griffin

580
Citations
PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial

Paul W. Armstrong;N. Bett;D. Brieger;D. Chew

508
Citations
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant

Herman E. Branson;Herman E. Branson;Richard Marble;Richard Marble;Jacob Katz;Jacob Katz;John H. Griffin;John H. Griffin

469
Citations
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V

Carol A. Fulcher;Joyce E. Gardiner;John H. Griffin;Theodore S. Zimmerman

449
Citations
Activated protein C resistance caused by Arg506Gln mutation in factor Va

JudithS. Greengard;Xi Sun;Xiao Xu;JoseA. Fernandez

427
Citations
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII.

B N Bouma;J H Griffin

399
Citations
Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII).

John H. Griffin

395
Citations
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor

John H. Griffin;Charles G. Cochrane

392
Citations
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles.

G Tans;J Rosing;MC Thomassen;MJ Heeb

388
Citations
Safety and Cost-Effectiveness of Early Discharge After Primary Angioplasty in Low Risk Patients With Acute Myocardial Infarction

Cindy L. Grines;Dominic L. Marsalese;Bruce Brodie;John Griffin

366
Citations
Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C

Edward J. Kerschen;José A. Fernandez;Brian C. Cooley;Xia V. Yang

366
Citations